PTCT -
PTC Therapeutics, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 76.54 2.27 (2.97%) |
0.0 (0.01%) |
0.0 (0.0%) |
-1.02 (-1.28%) |
--- |
2.27 (2.97%) |
--- |
--- |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Earnings & Ratios
- Basic EPS:
- -0.83
- Diluted EPS:
- -0.83
- Basic P/E:
- -94.9518
- Diluted P/E:
- -94.9518
- RSI(14) 1m:
- 35.36
- VWAP:
- 78.8
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
What's Going On With Royalty Pharma Stock Wednesday?
Dec 31, 2025 15:47
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
Dec 29, 2025 21:40
Here's Why Shares in PTC Therapeutics Soared This Week
Sep 05, 2025 12:35
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Jul 17, 2025 05:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Jun 02, 2025 17:55
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Jun 02, 2025 17:52
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - Global $5.52 Bn Market Trends, Opportunities, and Forecasts, 2020-2030F
May 29, 2025 14:56
Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsight
May 26, 2025 17:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Aug 03, 2024 19:41
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ... - GlobeNewswire
Jul 09, 2024 18:01